Shin Nippon Biomedical Laboratories Subsidiaries, Tokai Pharmaceuticals to Collaborate in Nasal Drug Delivery Technology.Tokyo, Japan, Nov 25, 2005 - (JCNN JCNN Japan Corporate News Network ) - Shin Nippon Biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. Laboratories (SNBL SNBL Sioux City and New Orleans Barge Line SNBL Snow Blower Unit (on mine trains) ) announced on November 24 that its two subsidiaries Translational Research (TRL TRL In currencies, this is the abbreviation for the Turkish Lira. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ) and Bioactis (BA) have agreed with Tokai Pharmaceuticals (TP) to collaborate in the field of nasal drug delivery technology. The SNBL subsidiaries specialize in nasal drug delivery: Translational Research has expertise in drug delivery technologies designed for insulin, morphine morphine, principal derivative of opium, which is the juice in the unripe seed pods of the opium poppy, Papaver somniferum. It was first isolated from opium in 1803 by the German pharmacist F. W. A. and antiemetics, while Bioactis has developed Fit-lizer, a proprietary medical device for delivering agents to the nose. Tokai Pharmaceuticals is a Massachusetts bioventure company that specializes in endocrine treatment and has Apple Tree Partners as a majority shareholder. Under this partnership, TRL and BA will license their technologies and device to TP. Consequently, TP will strive to develop a nasal drug for endocrine and metabolic diseases. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion